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Abstract:
 
Epigenetics is the study of heritable changes in gene expression that occur without
changes in DNA sequence. It has a role in determining when and where a gene is expressed during
development. Perhaps the most well known epigenetic mechanism is DNA methylation whereby
cytosines at position 5 in CpG dinucleotides are methylated. Histone modification is another form of
epigenetic control, which is quite complex and diverse. Histones and DNA make up the nucleosome
which is the structural unit of chromatin which are involved in packaging DNA. Apart from the cru-
cial role epigenetics plays in embryonic development, transcription, chromatin structure, X chro-
mosome inactivation and genomic imprinting, its role in an increasing number of human diseases is
more and more recognized. These diseases include cancer, and lung cancer in particular has been
increasingly studied for the potential biological role of epigenetic changes with the promise of better
and novel diagnostic and therapeutic tools.
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INTRODUCTION
 
Lung cancer is a major public health problem in the
world and remains a leading cause of cancer-related
deaths but its impact in developed and developing
Asian countries is also devastating.
 
1–3
 
 It is thought that
over 1.2 million people died from lung cancer in 2001,
with the majority coming from low- and middle-
income countries.
 
4
 
It is well known that cancer is a genetic disease, in
that aberration of key genetic and thereby molecular
pathways are critical for carcinogenesis. Such key
events have been called hallmarks of cancer and have
recently been reviewed.
 
5
 
 There is also increasing evi-
dence for a major role of epigenetic aberrations in
lung and many other cancers. Why epigenetic alter-
ations occur in cancer is not well understood
although theories include this response being
induced from sustained cellular stress.
 
6
 
 This review
seeks to provide the reader with a summary of the
research to date in this field and the potential impli-
cations for clinicians involved with lung cancer
patients. Recent reviews and key primary citations
will be listed to enable further reading while ensuring
brevity.
 
EPIGENETICS
 
Epigenetics in the study of heritable changes in gene
expression that occur without changes in DNA
sequence. The human DNA sequence and an associ-
ated near complete list of genes is known thanks to
the success of the Human Genome Project. However,
the place and timing of expression of specific gene
expression is complex and influenced by epigenetic
modification. Thus, epigenetic modifications are her-
itable during cell division but do not alter the DNA
sequence.
Epigenetic mechanisms include 
 
DNA methylation
 
,
as well as post-translational modification of core
histone proteins by acetylation, phosphorylation
and methylation, often called 
 
histone modification
 
.
These mechanisms contribute to dynamic patterns of
gene expression during cell cycling as well as to phys-
iological processes of genomic imprinting and X
chromosome inactivation. Although different pro-
cess, recent data indicate that DNA methylation and
histone modifications may be mechanistically linked.
The dynamics of genetic and epigenetic silencing are
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complex and have been reviewed recently by Jones
and Baylin.
 
7
 
DNA METHYL ATION
 
In mammals, DNA methylation involves covalent
modification at the fifth carbon position of cytosine
bases that are located 5
 
′
 
- to a guanosine in a
CpG dinucleotide (CpG dinucelotides are under-
represented in much of the genome but are found to
be concentrated in short regions called CpG islands).
Most CpG islands are located in the promoter regions
of mammalian genes and are generally unmethylated
in normal cells. The mammalian DNA methylation
process requires two components, the DNA methyl-
transferases (DNMTs) and the methyl CpG binding
proteins (MBDs)—summarized in recent reviews.
 
8,9
 
DNMTs establish and maintain methylation patterns
whereas MBDs are thought to be involved in ‘reading’
methylation marks. Potential mechanisms include
spreading of DNA methylation from repetitive
sequences into promoter-associated CpG islands
secondary to loss of transcriptional activators, gain
of methylation secondary to hyperexpression of
transcriptional repressors, primary hypermethylation
because of hyperexpression of methyltransferases,
and interallelic transfer of methylation via gene
pairing.
 
10
 
In brief a recently proposed model of DNA methy-
lation and cancer proposes that global hypomethyla-
tion in at-risk cells contributes to genomic instability
through increased mitotic recombination events,
whereas CpG island methylation in cancer cells leads
to transcriptional silencing of growth regulatory
genes.
 
8
 
DNA hypomethylation in lung cancer
 
The link between cancer and abnormal methylation
has been known since 1983, with the demonstration
that cancer genomes are relatively hypomethylated
compared with normal counterparts.
 
11
 
 Hypomethyla-
tion in cancer cells is thought to be primarily resulting
from loss of methylation from repetitive regions of the
genome, with resulting genomic instability.
 
8
 
 Apart
from global genomic demethylation which in many
cancers is an early event, gene specific hypomethyla-
tion also occurs which can result in functional
changes in gene expression.
Studies of oncogene transformed normal human
bronchial epithelial (NHBE) cells and clinical lung
cancer samples have demonstrated alterations in
methylation
 
12,13
 
 during lung carcinogenesis. The
global demethylation is known to result in the dere-
pression of parasitic DNA, loss of imprinting and up-
regulation of the expression of a number of usually
silent genes. Examples of genes altered in these ways
include loss of imprinting of the H19, IGF2 and MEST
genes. Imprinting is the epigenetic modification in a
specific parental chromosome that leads to differen-
tial expression of the two alleles in the offspring, thus
loss of imprinting is loss of the normal allele specific
gene expression which may result in deregulated cell
growth. Other genes up-regulated as a result of global
hypomethylation include those encoding cancer tes-
tes antigens (CTAs) proteins including the MAGE
family (recently reviewed by Schrump
 
9
 
).
 
DNA hypermethylation in lung cancer
 
In contrast, site specific hypermethylation of the
often unmethylated CpG islands in gene promoters is
now the most well characterized epigenetic modifica-
tion in cancer. It is found in nearly every human can-
cer type and is associated with transcription silencing
of gene expression. The genes silenced by promoter
hypermethylation tend to be tumour or growth sup-
pressor genes, and is an alternative to the classic loss
of one tumour suppressor gene (TSG) and mutation
of the other to satisfy Knudson’s two-hit hypothesis.
Indeed there are regions of chromosomes where allele
loss and hypermethylation may be the predominant
method on TSG inactivation, for example, RASSFI1 at
chromosome 3p21 and HIC1 are 17p13.3.
It is known that exposure to cigarette smoke
induces lung cancer in mice via both genetic and epi-
genetic pathways.
 
14
 
 Indeed some of the DNA methy-
lation changes involve the same genes that are altered
in human lung cancers.
 
15
 
 There are now many reports
of somatically acquired DNA methylation in the genes
involved in lung cancer. We have previously reported
on methylation specific PCR (MSP—see below) to
examine gene promoter methylation in lung cancer.
DNA was examined from 107 resected NSCLC and
corresponding normal lung tissue.
 
16–18
 
 Methylation in
the tumour samples was detected in 40% for 
 
RAR
 
b,
26% for 
 
TIMP-3
 
, 25% for 
 
p16
 
INK4a
 
, 21% for 
 
MGMT
 
, 19%
for 
 
DAPK
 
, 18% for 
 
ECAD
 
, 8% for 
 
p14 ARF
 
 and 7% for
 
GSTP1
 
, whereas it was not seen in the vast majority
of the corresponding non-malignant tissues. A total of
82% of the NSCLCs had methylation of at least one of
these genes; 37% had one gene methylated, 22% had
two genes methylated, 13% had three genes methy-
lated, 8% had four genes methylated and 2% had
five genes methylated. Aberrant 
 
p16
 
INK4a
 
 and 
 
FHIT
 
methylation corresponded with down-regulation
 
16,19
 
of gene expression. Thus, we and others have docu-
mented examples of epigenetic gene silencing
by 
 
de novo
 
 methylation of TSGs in lung cancers,
for example, 
 
Rb
 
, 
 
VHL
 
, 
 
p16
 
INK4a
 
, 
 
DAPK
 
, 
 
GSTP1
 
 and
 
MGMT
 
.
 
16–18
 
Many other genes are now shown to be methylated
to varying degrees in the different subtypes of lung
cancer, from primary lung cancers and also lung can-
cer cell lines. These include genes such as TSLC1;
 
20
 
CDH13,
 
21
 
 hSRBC,
 
22
 
 SPARC,
 
23
 
 DBC1.
 
24
 
 The genes
altered by DNA methylation include those involved
in cell cycle regulation (e.g. p16), DNA repair (e.g.
MGMT), apoptosis (e.g. DAPK, caspase 8, FAS,
TRAILR1), RAS signalling (RASSF1A, NORE1A) and
invasion (e.g. cadherins, TIMP3, laminin family) with
more detailed lists available from recent reviews.
 
25,26
 
Some of these pathways affected by epigenetic
change are those described as being hallmarks of
cancer.
 
5
4
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Detection of DNA methylation
 
One of the major reasons for the explosion in knowl-
edge regarding tumour methylation is thanks to the
rapid technological advances in this area. Frommer
 
et al
 
. demonstrated that bisulphite deamination of
cytosine and 5-methylcytosine differentially to yield
uracil and thymine, respectively, coupled with poly-
merase chain reaction (PCR) techniques allowed
simplified analysis of DNA methylation.
 
27
 
 These days,
the very sensitive bisulphite-based MSP is perhaps
the most popular tool for examining DNA methyla-
tion patterns (refer Fig. 1). The principles of MSP
and other methylation detection techniques, such
as restriction digestion by methylation-sensitive
enzymes, COBRA, PyroMeth, SnaPmeth, bisulphite
SSCP, bisulphite sequencing have been recently
reviewed.
 
28
 
 Some techniques such as restriction
landmark genomic scanning (RLGS) and arbitrarily
primed PCR (AP-PCR) are genome wide techniques
(often methylation-sensitive restriction enzyme-
based), for analysing the DNA methylation status of
CpG islands
 
7
 
 (refer Fig. 2). Newer techniques such as
array-based epigenomics testing, the high through-
put MethyLight or MALDI-TOF mass spectrometry
are now increasingly reported.
 
29
 
Characteristics of DNA methylation changes in 
lung cancer
 
The profile of aberrant DNA methylation differs
between cancers of different cell types.
 
30
 
 Even in lung
cancers, there appears to be heterogeneity in the fre-
quency of DNA methylation changes between lung
 
Figure 1
 
A representative gel showing methylation-
sensitive PCR (MSP) of the p16 gene. DNA from four
samples were bisulphite modified to convert unmethylated
cytosines into uracil. The treated DNA was then amplified
with two sets of primers designed to anneal to either regions
containing unmethylated cytosines (um) or methylated
cytosines (m). In this gel only sample 3 contains methylated
cytosines at the p16 promoter region tested.
 
Figure 2
 
Representative
gel showing methylation-
sensitive arbitrarily
primed PCR (MS-
APPCR). DNA was
pooled into two groups
of five samples, digested
with the restriction
enzymes 
 
Rsa
 
I, 
 
Rsa
 
I/
 
Hpa
 
II (methylation-
sensitive), 
 
Rsa
 
I/
 
Msp
 
I
(methylation insensitive)
and amplified with GC-
rich primer sets in the
presence of radiola-
belled 
 
33
 
P-dATP. The PCR
products were then
resolved on a 5% poly-
acrylamide gel. The box
region is magnified. The
arrow indicates a differ-
entially methylated band
in the tumour sample as
compared with the
corresponding normal
sample.
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cancer subtypes, for example, NSCLC compared with
SCLC.
 
26,31
 
In addition, the study of invasive lung cancers, pre-
neoplasia and normal tissues afford the chance to
understand the timing of methylation changes. Like
the genetic multistep progression model of lung
cancer, it is likely that there are increasing numbers
of epigenetic alterations as a predisposed cell
progresses towards invasive cancer. One such model
suggests that the accumulation of epigenetic change
parallels conventional morphological abnormalities
that have long been recognized for squamous carci-
nomas.
 
13
 
 Indeed, aberrant methylation of the p16
gene has been known for some years to be an early
event in lung cancer development.
 
32
 
 Further support
for DNA methylation-induced gene silencing comes
from animal models exposed to tobacco carcino-
gens.
 
15
 
 Moreover, different carcinogens appear to
have specificity for inducing various epigenetic
alterations.
Thus, while some DNA methylation events occur
early in lung cancer, and multiple gene promoters
are aberrantly methylated in invasive lung cancers,
the challenge is to translate this knowledge into
better epigenetic biomarker-based methods of lung
cancer detection and diagnosis, prognostication and
therapeutics.
 
DNA methylation—lung cancer diagnostics
 
In many cancers DNA methylation changes can be
detected in corresponding body fluids. This includes
lung cancer, where MSP detection of methylation
reveals detectable methylation of various promoters
in sputum, bronchial lavages, peripehral blood, and
where tumour and serum DNA methylation patterns
are closely related.
 
25
 
 Specific genes affected include
p16 (sputum, bronchial lavage, pleural lavage),
MGMT (sputum, bronchial lavage), RARb and DAPK
(bronchial lavage) and hMLH1 (sputum)—summa-
rized by Miyamoto.
 
33
 
 Thus, DNA methylation is a
promising tool for early diagnosis from body fluids,
including peripheral blood which is known to contain
circulating tumour free DNA. So far, most studies
have been relatively small case control studies and
assays not standardized leaving questions as to vary-
ing sensitivity and specificity. Nonetheless, prospec-
tive longitudinal studies are being performed and the
use of a panel of putative DNA methylation markers
for detecting early lung cancer remains a definite
future diagnostic possibility, especially with rapidly
changing technologies. Like all tumour biomarkers,
however, appropriate study designs and independent
validation of robust tests are needed to ensure their
translation to the clinic.
Risk-prediction is another aspect of the early detec-
tion paradigm, where accurate prediction of lung
cancer risks afford the chance for primary prevention
(smoking cessation) and secondary prevention (e.g.
chemoprevention) and well and disease screening
(e.g. optimization of helical low-dose CT screening
strategies). For instance, a recent study showed that
concomitant methylation of multiple gene (MGMT,
ras effector homologue 1, DAPK and PAX5a) pro-
moters in sputum is strongly associated with lung
cancer risk.
 
34
 
 Again, properly designed large scale
population-based studies are required.
 
DNA methylation—lung cancer prognostics
 
Lung and other cancer outcomes are only partially
predicted by gross tumour characteristics such as
pathological subtype or TNM stage, and patient char-
acteristics such as performance status. Apart from
these conventional prognostic factors, increasing evi-
dence indicate that molecular characterization may
provide refined information as to outcome and thus
guide the choice of therapies. Molecular predictive
factors include genetic and epigenetic factors, some
of which may be able to predict relative response to
specific therapies and other toxicities from drugs. In
addition, there may also be prognostic factors which
are related to the biology of the tumour such as
growth rate and metastatic behaviour. Much interest
has been centred on genetic profiling through gene
expression chips, but epigenetic or epigenomic fac-
tors are very likely to have a complementary role in
the future. For instance, methylation-dependent
transcriptional silencing of 14-3-3sigma, a major G2-
M checkpoint control gene, appears to be an inde-
pendent prognostic factor for survival in NSCLC
patients receiving platinum-based chemotherapy
which can be detected in the serum, thus obviating
the need for tumour tissue analysis.
 
35
 
DNA methylation—lung cancer therapeutics
 
Inhibition of DNA methylation as 
anticancer therapy
 
In foetal development epigenetic control of gene
expression is a dynamic process, attesting to the
potential for reversal of DNA methylation. The dem-
ethylating action of 5-azacytidine was first described
in 1980,
 
36
 
 and regained scientific interest when the
therapeutic effect of low doses of the deoxy derivative
5-aza-2
 
′
 
-deoxycitidine was reported in haematologi-
cal malignancies.
 
37,38
 
 Nucleoside analogues of cyti-
dine incorporate into DNA and specifically inhibit
DNMTs resulting in hypomethylation and reactiva-
tion of previously silenced hypermethylated genes,
for example, the P15/INK4B gene in patients with
myelodysplasia.
 
39
 
 The drugs are cytotoxic, causing
myelosuppression in high doses. Instability of the
cytosine analogues in aqueous solution limits their
clinical application. A newer orally active com-
pound (zebularine) with similar actions to 5-aza-2
 
′
 
-
deoxycitidine is capable of restoring imprinting
patterns in tumour cells by demethylation
 
40
 
 and, in
association with reactivation of p16, suppresses the
growth of human bladder cancer xenografts.
 
41
 
 Other
agents under current investigation for their demeth-
ylating activity include procaine,
 
42
 
 hydrallazine,
 
43
 
epigallocathecin-3-gallate (green tea polyphenol),
 
44
 
and s-adenosyl methionine inhibitors.
 
42
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Experimentally, transcriptional reactivation by
the nucleoside analogues is neither complete nor
universal
 
45
 
 suggesting that other silencing mecha-
nisms may need to be addressed to achieve a clinical
outcome in cancer patients. DNA methylation by
methyltransferases leads to interactions with methy-
lated DNA binding proteins, histone modification,
and chromatin restructuring and each of these ele-
ments of epigenetic silencing could potentially be tar-
geted therapeutically, as already described for histone
deacetylase inhibitors (HDACi). However, the obser-
vation that HDACi can restore expression of un-
methylated genes but not genes with methylated
promoters attests to the dominance of DNA methyla-
tion in transcriptional repression,
 
46
 
 and therefore its
importance as a therapeutic target. Synergism
between low-dose demethylating nucleoside ana-
logues and histone deacetylases (HDACs) in lifting
gene silencing
 
47–49
 
 leads to an expectation of
improved clinical responses from combination ther-
apy directed at cancer-related epigenetic aberrations.
Other possible avenues of therapeutic exploration
include methyltransferase inhibition independent of
binding to the replication fork of DNA, disruption of
DNA methyl binding proteins, and interference with
methylation and phosphorylation modification of
histones.
 
Demethylating agents in lung cancer
 
Preclinical
In vitro
 
 and preclinical studies indicate that restoring
the function of genes silenced by methylation in
lung cancer could produce an antitumour effect by
inducing growth arrest,
 
48
 
 apoptosis,
 
50
 
 inhibition of
angiogenesis,
 
51
 
 or modulation of immunological
recognition and targeting.
 
52
 
 In murine models of
NNK-induced lung tumours 5-aza-2
 
′
 
-deoxycitidine
reduced tumour incidence, both alone
 
53
 
 and in com-
bination with HDACi,
 
49
 
 indicating chemopreventive
potential for demethylating agents.
 
Clinical
 
Lung cancer patients included in clinical phase 1/2
studies of nucleoside analogue demethylating agents
in solid tumour patients with extensive disease have
not generally shown objective disease responses
 
25
 
 but
increased foetal haemoglobin synthesis during treat-
ment indicates that gene reactivation by demethyla-
tion is probably occurring in these patients.
 
54
 
 A phase
1/2 clinical trial of single agent 5-aza-2
 
′
 
-deoxycitidine
was associated with 5 years survival in one of 15
non-small cell carcinoma patients,
 
55
 
 but no clinical
responses were observed in the lung cancer patients
included on a phase 1 study of this agent in combina-
tion with cisplatin.
 
56
 
In the light of interactions outlined above, the
combination of low-dose demethylating agents and
HDACi is a rational path to follow in clinical trials.
Recent investigations have further defined the depen-
7
 
dency of chromatin mediated gene repression on
DNA methylation, through induction of signature
histone modifications representing transcriptional-
activation marks and loss of silencing marks.
 
57,58
 
Clinical trials of this approach are now underway in
lung cancer patients, for example, the phase 1 trial
of 5-aza-2
 
′
 
-deoxycitidine in combination with
depsipeptide.
 
59
 
Future directions in therapeutic targeting of 
DNA methylation
 
Most currently known demethylating agents act glo-
bally. Therefore, they may also theoretically disrupt
essential methylation or augment hypomethylation
of retrotransposons and repetitive DNA which have in
turn been linked to chromosomal instability and
nuclear disorganization.
 
60,61
 
 This consideration is par-
ticularly relevant to the future application of methy-
lation inhibiting strategies in preventive settings,
such as high-risk smokers. However, the clinical tox-
icities of demethylating agents have not supported
concerns over the possibility of large scale gene
activation. This is perhaps because transcription in
normal cells is not commonly controlled by CpG
promoter methylation and, where this is the case,
reactivation is not easily achieved by demethylation
alone, for example, X chromosome inactivation is
unaffected by 5-azacytidine.
 
62
 
Future directions for clinical therapies targeting
epigenetic pathways in lung cancer are to overcome
limitations of nucleoside analogue demethylating
agents imposed by formulation instability, to deter-
mine optimal dosing schedules to sustain demethyla-
tion effects while minimizing myelosuppressive and
other side-effects, to define the clinical potential of
non-nucleoside methylation inhibitors such as
-epigallocatechin-3-gallate, and selenium com-
pounds, and to evaluate novel demethylating agents
such as the psammaplins, small molecule methyl-
transferase inhibitors and oligonucleotides.
Proof of connection between administration of
therapeutic agents and a tumour response directly
dependent on demethylation-induced re-expression
of critical genes is still awaited. Further development
of clinically useful tests of demethylating activity is
warranted to improve on surrogate indicators such as
foetal Hb and demethylation of imprinted genes.
Measurement of 5-methylcytosine DNA levels with
high performance capillary electrophoresis could
provide a quantitative indicator of molecular effect in
blood and other clinical samples.
 
63
 
Methods of achieving gene-specific demethylation
rather than global demethylation need to be
explored, as do novel methods of targeting epigenetic
modifications. Because synthetic transcription fac-
tors and short interfering RNAs targeting promoter
regions are able to induce DNA methylation to affect
specific gene expression,
 
64,65
 
 approaches targeting
demethylation to specific regions may be able to
overcome problems arising from non-specific gene
derepression.
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HISTONE MODIFICATION IN 
LUNG CANCER
Function of HDACs
The packaging of DNA affects its transcription.66
Chromosomes are organized into coiled chromatin
fibres, which are themselves made up of units
(nucleosomes) comprising a central core of histone
proteins around which DNA is coiled.67 This con-
densed structure renders the DNA transcriptionally
inactive by reducing interaction between the DNA
and proteins involved in DNA transcription and
replication. In contrast, chromatin structure can be
reversibly remodelled through uncoiling, in order to
allow access to DNA-binding factors and activate
transcription. A major remodelling process is histone
acetylation, in which histone acetyltransferases
(HATs) add acetyl groups to lysine residues on the
histone N-terminal tails which protrude from the
nucleosome complex.68 Histone acetylation leads to a
loss of positive charge, reduced affinity between his-
tones and DNA, and consequently uncoiling to allow
access to RNA polymerase and transcription factors.67
HATs are therefore transcriptional coactivators.
Conversely, HDACs remove acetyl groups, and act
as transcriptional repressors. Histone deacetylation is
mediated by DNA methylation through binding of
repressor proteins in methylated CpGs in DNA.
Hence post-translational modification of histones by
acetylation and deacetylation represents a major
mechanism of transcription regulation at the chro-
matin level, thereby influencing gene expression.66 At
least 18 human HDAC enzymes have been identi-
fied.69 The classical HDAC family consists of Class I
(HDAC1, 2, 3 and 8) and Class II (HDAC4, 5, 6, 7, 9 and
10) HDACs, with HDAC11 showing overlapping fea-
tures. Class I HDACs are localized to the nucleus,
whereas Class II HDACs traffic to and from the
nucleus.66 HDACs are involved in many biological
processes, including regulation of cell cycling, cell
proliferation, differentiation, cell death, DNA replica-
tion and mitosis, and the development of cancer.69,70
Role of HDAC in cancer
The biological role of HDAC in human cancers has
recently been reviewed.69,71 Imbalance of acetylation
and deacetylation has been implicated in the patho-
genesis of haematological and solid tumours.71 To
explore the effects of HDAC aberrations in cancer,
HDAC and HDACi have been studied in a variety of
cancer cell lines, because immortalized cell lines pro-
vide useful ex vivo models of cancer biology for test-
ing of anticancer agents. Studies of the pathogenesis
of leukaemia have provided much of the information
about the role of HDAC in cancer.71 In acute promye-
locytic leukaemia, there is arrest of leukaemic cells in
the proliferative phase, preventing mature differenti-
ation of cells.71 This is because of the presence of aber-
rant retinoic acid receptor fusion proteins which
associate excessively with HDAC complexes, leading
to transcriptional silencing. With the addition of
pharmacological levels of retinoic acid treatment,
there is a release of HDAC complexes, allowing tran-
scriptional activation and myeloid differentiation.71
Other examples of translocation products in haema-
tological tumours include transcriptional repressor
LAZ3/BCL6 in non-Hodgkin’s lymphoma and the
AML1-ETO fusion protein in acute myeloid leu-
kaemia.71 In these diseases, HDACs are also recruited
excessively, leading to transcriptional repression and
downstream effects that favour oncogenesis.
HDAC overexpression has been found in solid
tumours including breast, gastric, oesophageal and
colon cancers, and variably linked with prognosis.69
The potential mechanisms of action of HDAC have
been explored in various tumour cell lines. Histone
acetylation status would be expected to correlate with
the level of gene expression in cancer cells. In a study
of gastric cancer cell lines, genomic fragments within
histones were analysed to identify differential gene
expression with various deacetylation status.72 The
level of histone acetylation in the gastric cancer cells
correlated with the level of gene expression of a
number of cancer-related genes, including several
involved in cell cycling. This was further demon-
strated in a study of resected oesophageal squamous
cell cancers in which the expression of metastasis-
associated protein (MTA1) and acetylation of histone
4 were determined using immunohistochemistry.73
Deacetylation of histone 4 correlated with overex-
pression of MTA1, which predicted tumour invasion
of the oesophageal wall, lymph node metastasis and
poorer prognosis. Histone acetylation and deacetyla-
tion have been studied in relation to other pathways
involved in oncogenesis. Apoptosis leads to pro-
grammed cell death and an antitumour effect. A study
of a breast cancer cell line showed that epidermal
growth factor induces the NF-κB-mediated associa-
tion of HDAC1 with the death receptor 5 gene, which
is one of the receptors for the tumour necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL).74
The observed deacetylation leads to an antiapoptotic
and oncogenic effect, and therefore provides ratio-
nale the use of HDACi in the treatment of cancer.
Finally, a tangible link between HDAC overexpression
and tumour pathways was also recently shown in a
study of colon cancer, in which resected specimens
showed increased expression of HDAC2.75 HDAC2
prevented apoptosis in the colon cancer cell line HT-
29 and was a requisite for cell survival. Furthermore,
these authors demonstrated in mice that loss of the
TSG, adenomatous polyposis coli (APC), induced
HDAC2 expression through the Wnt and c-Myc path-
ways. Thus, the results from studies of haematological
and solid tumours suggests that blocking the inap-
propriate transcriptional repression of HDACs would
be a promising strategy for antitumour therapy.
HDAC expression in lung cancer
Several studies have examined HDAC expression in
lung cancer resection specimens. In a study of 102
non-small cell lung cancer resection specimens, the
mRNA and protein expression of HDAC1 was
Epigenetics of lung cancer 7
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increased in patients with Stages III and IV lung
cancer, compared with Stage I or II.76 There was no
difference in mRNA expression between tumour and
adjacent non-tumour lung tissue. In a study of 72
non-small cell lung cancer resection specimens, the
mRNA expression of HDAC1 to 8 and 10 was corre-
lated with prognosis.77 Low expression of Class II
HDACs, in particular HDAC10, showed association
with poorer prognosis after surgery. The protein
expression of HDAC3 was found to be up-regulated in
squamous cell lung cancer specimens using antibody
arrays and confirmed by immunoblot analysis.78 Col-
lectively, it can be postulated from these preliminary
studies that HDACs repress critical gene pathways
involved in protecting against lung cancer and there-
fore HDAC activity may promote tumorigenesis. In
contrast, in chronic obstructive pulmonary disease,
which is another example of a smoking-induced lung
disease, there is a reduction in lung HDAC anti-
inflammatory activity that correlates with disease
progression.79 Only one study has examined the role
of genetic variation in HDAC genes in lung cancer.
There was no association of polymorphisms in the
HDAC3, 4 and 5 genes and the risk of lung cancer in a
study of 432 lung cancer patients and 432 controls in
Korea.80
HDAC inhibitors
Given the potentially pathogenic role of HDAC and
deacetylation in cancer, HDACi have emerged as
novel anticancer agents.71 HDACi are compounds that
bind to the active zinc site of the catalytic domain of
HDAC.69 Several classes of HDACi exist, including
hydroxamate, cyclic peptide, aliphatic acid and
benzamide classes.69 Examples of HDACi include
trichostatin A, sodium butyrate, suberoylanilide
hydroxamic acid (SAHA), FK228 and valproate. The
exact mechanism of action of HDACi remains
unclear.69 It is known that HDACi induce growth
arrest of cells, terminal differentiation, caspase-
dependent apoptosis and cell death. However, nor-
mal cells appear to be less sensitive to the effects of
HDACi than transformed cells.69 Furthermore, inhibi-
tion of HDAC may increase or decrease overall gene
expression, depending on the genes targeted. Binding
of HDACi to other non-histone regulatory proteins
also influences the alteration of transcriptional
activity.
Effect of HDACi on lung cancer cell lines
Initial studies in lung cancer cell lines suggested that
HDACi have inhibitory effects on cell cycling and pro-
mote apoptosis.9 Subsequent studies have further
investigated the effect of specific HDACi on chroma-
tin structure and phenotypes related to cell growth,
with the aim of confirming that HDACi have biologi-
cal effects in cells of lung origin. In a study of normal
lung fibroblasts, the HDACi trichostatin A dere-
pressed the activity of telomerase, whereas there was
no effect in non-small cell lung cancer cell lines.81 In
the A549 lung carcinoma cell line, treatment with the
HDACi sodium butyrate resulted in global histone
hyperacetylation, chromatin decondensation and
intense acetylation patterns at the periphery of the
nucleus.82 Treatment of the H69 small cell lung cancer
cell line with trichostatin A showed a chromatin
decondensation pattern of nuclear texture.83
Together, these studies of chromatin remodelling
indicate that HDACi have biological effects in lung
cancer cell lines.
The role of pathways that interact with HDACs has
been investigated with HDACi, to identify pathways
that influence the responsiveness of lung cancer cells
to HDACi. FK228, an HDACi, was tested in the A549
lung adenocarcinoma cell line and PC14, a lung ade-
nocarcinoma cell line that is relatively more resistant
to HDACi.84 In the A549 non-small cell lung cancer
cells, FK228 inhibited the Akt-mediated signalling
pathway in the A549 cells but not the resistant PC14
cells. In another study of A549 cells, the HDACi tri-
chostatin A was pro-apoptotic, as indicated by the
down-regulation of the antiapoptotic Bcl-2 protein,
up-regulation of the pro-apoptotic Bax protein and
activation of caspases.85 In a study of the small cell
lung cancer cell lines, H69 and H526, the HDACi
FR901228 induced caspase-dependent apoptosis
through the mitochondrial pathway, rather than the
death receptor pathway.86 Cyclooxygenase 2 (COX2)
mRNA expression was also decreased with trichosta-
tin A treatment, implicating involvement of the
cyclooxygenase pathway in mediating the anticancer
effect of trichostatin A. Hence these results show that
are complex, interrelated mechanisms of action of
individual HDACi on both deacetylation and non-his-
tone pathways, and these should be studied in detail
in order to understand lung cancer responsiveness to
HDACi treatment.
Combination therapy of HDACi and other agents
The effects of HDACi have been limited to a certain
extent by their activation of pathways that tend to
antagonize the antitumour effect. For example, non-
small cell lung cancer cell lines are relatively resistant
to the HDACi SAHA, despite SAHA having adequate
HDACi activity.87 The reason may be that SAHA stim-
ulates the activity of the transcription factor NF-κB
which is antiapoptotic and therefore further increases
cell survival. This has lead to the testing of combina-
tions of HDACi with other proven or putative antitu-
mour agents. The combination of the HDACi, SAHA,
with the chemotherapeutic agent, gemcitabine, was
tested in a study of non-small cell lung cancer cell
lines.88 SAHA with gemcitabine was found to enhance
apoptosis in the tumour cells, possibly through the
attenuation of SAHA-induced NF-κB activation by
gemcitabine. In another study focusing on NF-κB,
H322 and H460 lung cancer cell lines were treated
with trichostatin A and calphostin C (a protein kinase
C inhibitor).89 Using this combination, 90–96% of cells
underwent apoptosis, and there was an associated
reduction in induced NF-κB activation. Another
HDACi, N-acetyldinaline (CI-994), was tested in the
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A549 and LX-1 (squamous cell lung cancer) cell
lines.90 N-acetyldinaline treatment of the cells pro-
duced a concentration-dependent inhibition of cell
survival, an effect which was synergistic with gemcit-
abine or docetaxal treatment. Also in A549 cells,
the combination of TNF-related apoptosis-inducing
ligand (TRAIL) and either SAHA, trichostatin A or
sodium butyrate substantially increased apoptosis in
the cell line.91 Finally four non-small cell lung cancer
cell lines were treated with SAHA and bortezomib, a
proteosome inhibitor.92 The combination enhanced
reactive oxygen species generation and apoptosis,
leading to greater cell death than either agent singly.
Therefore, the use of adjunctive therapy improves the
antitumour efficacy of HDACi, overcoming some of
the limitations caused by activation of growth path-
ways by HDACi.
Other factors should be considered in designing tri-
als of HDACi with chemotherapy. The timing of the
administration of HDACi in relation to the chemo-
therapy is likely to be a critical factor. In a study of the
A549 lung cancer cell line, SAHA or sodium butyrate
HDACi agents were added to the cell culture the day
before, the day of or the day after the chemotherapy
agent, which in this study was the topoisomerase I
inhibitor, camptothecin.93 The HDACi was most effec-
tive in reducing cell survival when added after camp-
tothecin, when camptothecin had already caused
G2-M arrest of tumour cells. The timing of other lung
cancer therapy may also enhance the efficacy of
HDACi. HDACi may act as a radiosensitizer, as shown
in breast cancer cell line studies, by increasing mitotic
cell death in irradiated cells,94 although this effect has
not yet been shown in lung cancer cell lines.90
HDACi in lung cancer clinical trials
Phase 1/2 trials in solid tumours and haematological
malignancies have shown that HDACi are well toler-
ated.71 There have been two small clinical trials of
HDACi in lung cancer. The oral HDACi CI-994 was
studied in a phase 1 trial in 30 patients with advanced
solid tumours, of whom four had non-small cell lung
cancer.95 Analysis of all tumour subtypes (lung and
non-lung) showed that this oral agent was well toler-
ated when administered with paclitaxel and carbopl-
atin, and the fold increase of lymphocyte histone 3
acetylation was associated with better response rate.
In a phase 2 study of 47 patients with chemotherapy-
refractory lung cancer (mostly Stage IV), i.v. pivaloy-
loxymethyl butyrate was well tolerated and
demonstrated some anticancer activity.96 Further tri-
als of combination therapy of HDACi with other che-
motherapy agents are in progress. Thus, HDACi has
emerged as a promising new modality in the treat-
ment of lung cancer, and more detailed studies are
needed.
SUMMARY
Thus, increasing evidence paints the scenario
whereby epigenetic alterations such as DNA methyla-
tion and histone modifications (which may interact)
contribute to the molecular pathogenesis of lung can-
cer cells, in addition to the more widely known
genetic mutations found in all types of lung cancer.
Epigenetic alterations are relatively frequent,
affect multiple genes and in some cases occur early
during lung carcinogenesis. Furthermore, epigenetic
changes unlike genetic changes are potentially
reversible, leading to an intense study of potential
therapeutic translation. For these reasons, much
research is focussed on developing the diagnostic,
prognostic and therapeutic potential of these
changes. Efforts such the Human Epigenome Consor-
tium (HEC) and the proposed Human Epigenome
Project should go a long way to advancing our knowl-
edge, helping us to understand why (to date) epige-
netics is only rarely implicated in hereditary cancer
and thus hopefully lead to more effective treatments
in our fight against lung cancer.
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